SEC Filings | Vera Therapeutics

Filing date	Form	Description	View
March 30, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001140361-23-014836.pdf 0001140361-23-014836.rtf 0001140361-23-014836.xls View HTML
April 3, 2024	DEFA14A	Additional proxy soliciting materials - definitive	0001140361-24-017652.pdf 0001140361-24-017652.rtf 0001140361-24-017652.xls View HTML
March 19, 2021	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-21-003674.pdf 0000950123-21-003674.rtf 0000950123-21-003674.xls View HTML
January 4, 2022	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-22-000013.pdf 0000950123-22-000013.rtf 0000950123-22-000013.xls View HTML
May 13, 2021	EFFECT	EFFECT	9999999995-21-001922.pdf 9999999995-21-001922.rtf 9999999995-21-001922.xls View HTML
February 9, 2022	EFFECT	EFFECT	9999999995-22-000386.pdf 9999999995-22-000386.rtf 9999999995-22-000386.xls View HTML
June 13, 2022	EFFECT	EFFECT	9999999995-22-001773.pdf 9999999995-22-001773.rtf 9999999995-22-001773.xls View HTML
April 23, 2021	S-1	Registration statement for face-amount certificate companies	0001193125-21-129272.pdf 0001193125-21-129272.rtf 0001193125-21-129272.xls View HTML
February 7, 2022	S-1	Registration statement for face-amount certificate companies	0001193125-22-029746.pdf 0001193125-22-029746.rtf 0001193125-22-029746.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 10, 2021	S-1/A	Amended Registration statement for face-amount certificate companies	0001193125-21-155556.pdf 0001193125-21-155556.rtf 0001193125-21-155556.xls View HTML

Data provided by Kaleidoscope.